2018年　業績集

  1. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
    Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O’Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.
    Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.
    PMID: 30237262 Free PMC article. Clinical Trial.
  2. Clinical significance of tryptophan catabolism in Hodgkin lymphoma.
    Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S.
    Cancer Sci. 2018 Jan;109(1):74-83. doi: 10.1111/cas.13432. Epub 2017 Nov 29.
    PMID: 29080383 Free PMC article.
  3. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.
    Mori Y, Kinoshita S, Kanamori T, Kataoka H, Joh T, Iida S, Takemoto M, Kondo M, Kuroda J, Komatsu H.
    Intern Med. 2018 Sep 15;57(18):2753-2757. doi: 10.2169/internalmedicine.9879-17. Epub 2018 May 18.
    PMID: 29780156 Free PMC article.
  4. Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.
    Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S.
    Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3.
    PMID: 30076184 Free PMC article.
  5. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.
    Shimazaki C, Hata H, Iida S, Ueda M, Katoh N, Sekijima Y, Ikeda S, Yazaki M, Fukushima W, Ando Y.
    Intern Med. 2018 Jan 15;57(2):181-187. doi: 10.2169/internalmedicine.9206-17. Epub 2017 Nov 1.
    PMID: 29093404 Free PMC article.
  6. Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals.
    Masaki A, Ishida T, Suzuki S, Ito A, Narita T, Kinoshita S, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Iida S.
    Cancer Sci. 2018 Aug;109(8):2383-2390. doi: 10.1111/cas.13654. Epub 2018 Jun 27.
    PMID: 29845702 Free PMC article.
  7. Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K.
    Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17.
    PMID: 29478257 Free PMC article. Clinical Trial.
  8. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
    Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.
    Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.
    PMID: 30374808 Free PMC article.
  9. Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors.
    Aiki S, Okuyama T, Sugano K, Kubota Y, Imai F, Nishioka M, Ito Y, Iida S, Komatsu H, Ishida T, Kusumoto S, Akechi T.
    Jpn J Clin Oncol. 2018 Jan 1;48(1):61-67. doi: 10.1093/jjco/hyx159.
    PMID: 29136185
  10. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M.
    Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.
    PMID: 29260507 Clinical Trial.
  11. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
    Maruyama D, Tobinai K, Chou T, Taniwaki M, Shumiya Y, Iida S.
    Cancer Sci. 2018 Oct;109(10):3245-3252. doi: 10.1111/cas.13753. Epub 2018 Sep 5.
    PMID: 30058108 Free PMC article. Clinical Trial.
  12. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.
    Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.
    Oncol Lett. 2018 Jun;15(6):9450-9456. doi: 10.3892/ol.2018.8501. Epub 2018 Apr 16.
    PMID: 29928335 Free PMC article.
  13. A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma.
    Ri M, Suzuki K, Iida S, Hatake K, Chou T, Taniwaki M, Watanabe N, Tsukamoto T.
    Intern Med. 2018 Apr 1;57(7):939-946. doi: 10.2169/internalmedicine.9567-17. Epub 2017 Dec 8.
    PMID: 29225263 Free PMC article. Clinical Trial.
  14. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
    Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S.
    Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.
    PMID: 29712896 Free PMC article. Clinical Trial.
  15. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
    Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.
    PLoS One. 2018 May 8;13(5):e0196780. doi: 10.1371/journal.pone.0196780. eCollection 2018.
    PMID: 29738534 Free PMC article.
  16. Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer.
    Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y.
    Hepatol Res. 2018 Dec;48(13):1081-1091. doi: 10.1111/hepr.13229. Epub 2018 Aug 26.
    PMID: 30006955
  17. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
    Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K.
    Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19.
    PMID: 30027429 Clinical Trial.
  18. Improved clonality detection in Hodgkin lymphoma using a semi-nested modification of the BIOMED-2 PCR assay for IGH and IGK rearrangements: A paraffin-embedded tissue study.
    Han S, Masaki A, Sakamoto Y, Takino H, Murase T, Iida S, Inagaki H.
    Pathol Int. 2018 May;68(5):287-293. doi: 10.1111/pin.12660. Epub 2018 Mar 25.
    PMID: 29575591
  19. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits.
    Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S.
    Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. eCollection 2018 Feb 9.
    PMID: 29515784 Free PMC article.
  20. Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature.
    Yoshida M, Marumo Y, Naitoh I, Hayashi K, Miyabe K, Nishi Y, Fujita Y, Jinno N, Hori Y, Natsume M, Kato A, Iida S, Joh T.
    Intern Med. 2018 Jun 15;57(12):1725-1732. doi: 10.2169/internalmedicine.9818-17. Epub 2017 Dec 21.
    PMID: 29269682 Free PMC article.
  21. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, Tokunaga M, Utsunomiya A, Ito A, Kusumoto S, Iida S, Ueda R, Inagaki H.
    Blood. 2018 Aug 16;132(7):758-761. doi: 10.1182/blood-2018-02-835991. Epub 2018 Jun 21.
    PMID: 29930010 Clinical Trial. No abstract available.